Published • loading... • Updated
From bases to breakthroughs: Editing cancer’s weak spots with CRISPR
Summary by Wellcome Sanger Institute Blog
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
From bases to breakthroughs: Editing cancer’s weak spots with CRISPR
In the latest installment of our innovator blog series, we caught up with Dr Matthew Coelho, Cancer Research UK Career Development Fellow at the Wellcome Sanger Institute. Matthew works within the Somatic Genomics programme and is co-founder of BASE Rx alongside Group Leader, Dr Mathew Garnett.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
